Depression and ART Adherence in HIV+ Latinos
Status: | Completed |
---|---|
Conditions: | Depression, HIV / AIDS |
Therapuetic Areas: | Immunology / Infectious Diseases, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/17/2018 |
Start Date: | July 2008 |
End Date: | January 2012 |
Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border
The current HIV treatment adherence project was designed to adapt culturally and then pilot
test an empirically supported cognitive-behavioral therapy program for adherence and symptoms
of depression (CBT-AD)with HIV+ Latinos living on the U.S.-Mexico Border.
test an empirically supported cognitive-behavioral therapy program for adherence and symptoms
of depression (CBT-AD)with HIV+ Latinos living on the U.S.-Mexico Border.
Additionally, the investigators will assess the feasibility and efficacy of a novel
medication monitoring and reminder system (MedSignals®) in the form of an electronic pillbox
with monitoring and reminding functions that is available in a Spanish-language version. Our
hypotheses are grounded in a conceptual model proposing that the CBT-AD intervention will
improve problem-solving ability and decrease depressive symptomatology, which will directly
improve biomedical outcomes of HIV-1 RNA viral load and CD4 as well as indirectly improve
biomedical outcomes through increased motivation, improved memory, and better medication
adherence. Evaluating and implementing generalizable and sustainable mental health and
adherence interventions such as the ones proposed are urgently needed in the region to
improve HIV treatment outcomes and thwart the development and transmission of drug resistant
virus.
medication monitoring and reminder system (MedSignals®) in the form of an electronic pillbox
with monitoring and reminding functions that is available in a Spanish-language version. Our
hypotheses are grounded in a conceptual model proposing that the CBT-AD intervention will
improve problem-solving ability and decrease depressive symptomatology, which will directly
improve biomedical outcomes of HIV-1 RNA viral load and CD4 as well as indirectly improve
biomedical outcomes through increased motivation, improved memory, and better medication
adherence. Evaluating and implementing generalizable and sustainable mental health and
adherence interventions such as the ones proposed are urgently needed in the region to
improve HIV treatment outcomes and thwart the development and transmission of drug resistant
virus.
Inclusion Criteria:
- HIV+ participants (a) currently receiving HIV care at La Fe CARE Center (study site);
- 18 years of age or older;
- Latino (i.e., self-identified as being of Mexican heritage);
- English- or Spanish-speaking
- capable of giving informed consent;
- currently on a prescribed antiretroviral regimen;
- suboptimally adherent (i.e., demonstrated either by a VL load taken in the last 12
months that is above the undetectable threshold of 50 mL copies or self-reporting a
missed dose in the last two weeks);
- exhibiting some depressive symptomatology (i.e., scoring on the Beck Depression
Inventory-1A 10 or above), and (i) male or female (including transgender
Female-to-Male and Male-To-Female.
Exclusion Criteria:
- actively psychotic or so cognitively impaired that they cannot participate,
- so physically ill as to be unable to come to the clinic to participate in the
intervention, OR
- Report The use of crack, cocaine, heroin, OR methamphetamines to any extent in the
past 40 days.
- Those who are planning on being away from the area for any extended period during the
study (as in the case of seasonal workers) or whom
- have household members already enrolled in the study will also be excluded. We did
choose to restrict study eligibility to individuals of Mexican descent.
We found this trial at
1
site
Click here to add this to my saved trials